Home > Research > Publications & Outputs > Disparate STING signalling as a link between bl...

Electronic data

View graph of relations

Disparate STING signalling as a link between bladder cancer cell innate immune response and the immunostimulatory state of the tumour microenvironment following genotoxic therapies

Research output: Contribution to conference - Without ISBN/ISSN Poster

Published

Standard

Disparate STING signalling as a link between bladder cancer cell innate immune response and the immunostimulatory state of the tumour microenvironment following genotoxic therapies. / Walker, Thomas; Unterholzner, Leonie.
2024. Poster session presented at Cancer Research UK: Cancer and the host - tumour immunology, London, United Kingdom.

Research output: Contribution to conference - Without ISBN/ISSN Poster

Harvard

APA

Vancouver

Author

Bibtex

@conference{592ddb6e63134d98b50f684923adf909,
title = "Disparate STING signalling as a link between bladder cancer cell innate immune response and the immunostimulatory state of the tumour microenvironment following genotoxic therapies",
abstract = "ObjectivesA T cell-inflamed immunostimulatory tumour microenvironment (TME) is required for successful cancer cell clearance, and for checkpoint inhibitor immunotherapies, whilst a suppressive TME correlates with resistance and poor prognosis. Chemotherapy (CT) or radiotherapy (RT) can direct both immunostimulatory and immunosuppressive states. DNA damage can elicit cytosolic micronuclei which are detected by the DNA sensor cGAS and its adaptor STING. Nuclear DNA damage can also be detected via cGAS-independent STING activity which presents a distinct pro-inflammatory cytokine profile. We are investigating the role of DNA damage-driven innate immune responses in muscle-invasive bladder cancer. Bladder cancer presents with significant recurrence and mortality following standard-of-care cystectomy. Its high mutational load offers a favourable model system to study disparate STING pathway signalling following CT/RT and correlation with the TME immunoreactive state.MethodsWe are analysing a panel of muscle-invasive bladder cancer cell lines for their mechanistic innate immune responses following treatment with CT agents and IR which mirror UK NICE bladder cancer management guidelines. Micronuclei burden and activation states of cGAS-dependent and cGAS-independent STING signalling were determined through quantitative confocal microscopy, qRT-PCR and ELISA. ResultsBladder cancer cells display a range of cytotoxic and cytostatic responses following CT agent treatment. We find that sub-lethal CT doses cause an innate immune response in cancer cells, and that the cells in the panel differ in their ability to activate cGAS-dependent and independent STING signalling and the resulting spectrum of type I interferon and cytokine profiles. ConclusionsBladder cancer cytotoxic and innate immune STING activity states are highly relevant to the mechanistic understanding of responses to CT/RT. Ongoing work will integrate innate immune signatures with analysis of patient tissue. This offers relevance for triaging patients who could benefit from bladder-sparing CT/RT and immunotherapy eligibility.",
keywords = "Cancer, Innate Immunity, Tumour Microenvironment, patient outcomes, bladder cancer;, Chemotherapy, Radiotherapy",
author = "Thomas Walker and Leonie Unterholzner",
year = "2024",
month = may,
day = "7",
language = "English",
note = "Cancer Research UK: Cancer and the host - tumour immunology, CRUK Cancer and the host ; Conference date: 07-05-2024 Through 07-05-2024",

}

RIS

TY - CONF

T1 - Disparate STING signalling as a link between bladder cancer cell innate immune response and the immunostimulatory state of the tumour microenvironment following genotoxic therapies

AU - Walker, Thomas

AU - Unterholzner, Leonie

PY - 2024/5/7

Y1 - 2024/5/7

N2 - ObjectivesA T cell-inflamed immunostimulatory tumour microenvironment (TME) is required for successful cancer cell clearance, and for checkpoint inhibitor immunotherapies, whilst a suppressive TME correlates with resistance and poor prognosis. Chemotherapy (CT) or radiotherapy (RT) can direct both immunostimulatory and immunosuppressive states. DNA damage can elicit cytosolic micronuclei which are detected by the DNA sensor cGAS and its adaptor STING. Nuclear DNA damage can also be detected via cGAS-independent STING activity which presents a distinct pro-inflammatory cytokine profile. We are investigating the role of DNA damage-driven innate immune responses in muscle-invasive bladder cancer. Bladder cancer presents with significant recurrence and mortality following standard-of-care cystectomy. Its high mutational load offers a favourable model system to study disparate STING pathway signalling following CT/RT and correlation with the TME immunoreactive state.MethodsWe are analysing a panel of muscle-invasive bladder cancer cell lines for their mechanistic innate immune responses following treatment with CT agents and IR which mirror UK NICE bladder cancer management guidelines. Micronuclei burden and activation states of cGAS-dependent and cGAS-independent STING signalling were determined through quantitative confocal microscopy, qRT-PCR and ELISA. ResultsBladder cancer cells display a range of cytotoxic and cytostatic responses following CT agent treatment. We find that sub-lethal CT doses cause an innate immune response in cancer cells, and that the cells in the panel differ in their ability to activate cGAS-dependent and independent STING signalling and the resulting spectrum of type I interferon and cytokine profiles. ConclusionsBladder cancer cytotoxic and innate immune STING activity states are highly relevant to the mechanistic understanding of responses to CT/RT. Ongoing work will integrate innate immune signatures with analysis of patient tissue. This offers relevance for triaging patients who could benefit from bladder-sparing CT/RT and immunotherapy eligibility.

AB - ObjectivesA T cell-inflamed immunostimulatory tumour microenvironment (TME) is required for successful cancer cell clearance, and for checkpoint inhibitor immunotherapies, whilst a suppressive TME correlates with resistance and poor prognosis. Chemotherapy (CT) or radiotherapy (RT) can direct both immunostimulatory and immunosuppressive states. DNA damage can elicit cytosolic micronuclei which are detected by the DNA sensor cGAS and its adaptor STING. Nuclear DNA damage can also be detected via cGAS-independent STING activity which presents a distinct pro-inflammatory cytokine profile. We are investigating the role of DNA damage-driven innate immune responses in muscle-invasive bladder cancer. Bladder cancer presents with significant recurrence and mortality following standard-of-care cystectomy. Its high mutational load offers a favourable model system to study disparate STING pathway signalling following CT/RT and correlation with the TME immunoreactive state.MethodsWe are analysing a panel of muscle-invasive bladder cancer cell lines for their mechanistic innate immune responses following treatment with CT agents and IR which mirror UK NICE bladder cancer management guidelines. Micronuclei burden and activation states of cGAS-dependent and cGAS-independent STING signalling were determined through quantitative confocal microscopy, qRT-PCR and ELISA. ResultsBladder cancer cells display a range of cytotoxic and cytostatic responses following CT agent treatment. We find that sub-lethal CT doses cause an innate immune response in cancer cells, and that the cells in the panel differ in their ability to activate cGAS-dependent and independent STING signalling and the resulting spectrum of type I interferon and cytokine profiles. ConclusionsBladder cancer cytotoxic and innate immune STING activity states are highly relevant to the mechanistic understanding of responses to CT/RT. Ongoing work will integrate innate immune signatures with analysis of patient tissue. This offers relevance for triaging patients who could benefit from bladder-sparing CT/RT and immunotherapy eligibility.

KW - Cancer

KW - Innate Immunity

KW - Tumour Microenvironment

KW - patient outcomes

KW - bladder cancer;

KW - Chemotherapy

KW - Radiotherapy

M3 - Poster

T2 - Cancer Research UK: Cancer and the host - tumour immunology

Y2 - 7 May 2024 through 7 May 2024

ER -